Experiments to analyze the product of the equine herpesvirus type 1 (EHV-1) UL45 homolog were conducted. Using an antiserum generated against the carboxylterminal 114 amino acids of the EHV-1 UL45 protein, proteins of M r 32,000, 40,000, and 43,000 were detected specifically in EHV-1-infected cells. Neither form of the protein was located in purified virions of EHV-1 wild-type strain RacL22 or the modified live vaccine strain RacH, but UL45 was demonstrated to be expressed as a late (␥Ϫ2) protein. Fractionation of infected cells and deglycosylation experiments demonstrated that the EHV-1 UL45 protein represents a type II membrane glycoprotein. Deletion of the UL45 gene in RacL22 and RacH (L⌬45 and H⌬45) showed that UL45 is nonessential for EHV-1 growth in vitro, but that deletion reduced the viruses' replication efficiency. A marked reduction of virus release was observed although no significant influence was noticed either on plaque size or on the syncytial phenotype of the EHV-1 strain RacH.
INTRODUCTION
The Alphaherpesvirus equine herpesvirus type 1 (EHV-1) is an important pathogen of horses that causes rhinopneumonitis, late-term abortions, and neurological disorders (Allen and Bryans, 1986) . At least 76 proteins are encoded by EHV-1 (Telford et al., 1992) , most of which, especially the structural proteins, are conserved in the subfamily of the Alphaherpesvirinae. Twelve EHV-1 glycoproteins have been described and are named in accordance with membrane glycoproteins of herpes simplex virus 1 (HSV-1). Among these glycoproteins are homologs to glycoproteins B, C, D, E, G, H, I, K, L, and M, whereas glycoprotein 1/2 is unique for EHV-1 . Another glycosylated protein (gp10), the homolog of HSV-1 VP13/14, is not part of the viral envelope but is a component of the tegument (Whittaker et al., 1991) . In addition, several open reading frames (ORF) in Alphaherpesvirinae have been identified that could encode for additional membrane-associated proteins, some of which are carrying glycosylation consensus sites. Among these ORFs are homologs of the HSV-1 UL45 that have been described in HSV-2 (Cockrell and Muggeridge, 1998) , several avian herpesviruses like Marek's disease virus, and herpesvirus of turkeys or infectious laryngotracheitis virus (ILTV, Ziemann et al., 1998) , but also in feline herpesvirus 1 (FHV-1, Willemse et al., 1994) and in EHV-1 and EHV-4 (Telford et al., 1992 (Telford et al., , 1998 . Besides EHV-1 and EHV-4, however, no UL45 homologous ORFs have been detected in the genomes of such Varicelloviruses as varicella-zoster virus (Davison and Scott, 1986) , bovine herpesvirus 1 (Schwyzer et al., 1996) , and pseudorabies virus (PrV, Bras et al., 1999) . The amino acid homology between the predicted UL45 gene products is moderate, but they all contain a large internal hydrophobic domain McGeoch et al., 1988; Willemse et al., 1994; Cockrell and Muggeridge, 1998; Telford et al., 1998; Ziemann et al., 1998) . The M r 18,000 UL45 protein of HSV-1, a component of the virion, was classified as a true late protein, the expression of which is dependent on DNA synthesis (Visalli and Brandt, 1993) , whereas the 75% identical UL45 of HSV-2 was detected as early as 4 h p.i. (Cockrell and Muggeridge, 1998) . The latter localizes to cellular membranes in transfected Cos7 cells, in a pattern resembling the endoplasmatic reticulum (ER), but not to the cell-surface membrane. It was shown to be an integral type II membrane protein (Cockrell and Muggeridge, 1998) . Another type II membrane protein encoded by the US9 homolog of PrV was identified. The role of the uniquely tail-anchored US9 protein in the PrV life cycle is still under investigation, but it was shown to have an effect on virus spread in the rat nervous system (Brideau et al., 1998 (Brideau et al., , 2000 . Haanes et al. (1994) analyzed the effect of HSV-1 UL45 on the formation of gB-induced fusion observed in several HSV-1 syn mutants, and the protein was shown to be a mediator of fusion events late in HSV-1 infection. Insertion of a marker gene into the UL45 genes of HSV-1 or FHV-1 demonstrated that the protein is nonessential for replication of these viruses. While the HSV-1 mutant exhibited an influence on the plaque phenotype, no in vitro phenotype was reported for the FHV-1 mutant virus that replicated efficiently in cats (Visalli and Brandt, 1991; Willemse et al., 1994) . Despite that, the FHV-1 UL45 mutant did not cause FHV-1-related symptoms and was identified as a virulence factor (Willemse et al., 1994) .
Information on the structure and the function of several UL45 homologs has been acquired, but the proteins' functions are not yet fully understood. Therefore, the aims of this study were to determine the expression, the posttranslational modification(s), and the function of the EHV-1 UL45 homolog. ORF 15, the UL45 homologous locus in EHV-1, is known to be expressed as a ␥-2 gene that encodes a 0.9-kb mRNA that is 3Ј-coterminal with the gC transcript (Matsumura et al., 1993) . To characterize the EHV-1 UL45 gene product, specific antisera were generated and used to detect the protein in purified virions or in lysates of infected cells. Synthesis, processing, and subcellular localization of the UL45 protein were examined. Finally, the role of the EHV-1 UL45 homolog in EHV-1 replication in cell culture was assessed by characterizing UL45 deletion mutants constructed from EHV-1 strains RacH and RacL22 (Fig. 1) . The EHV-1 modified live vaccine strain RacH was chosen in addition to the virulent wild-type EHV-1 strain RacL22 for the generation of UL45 mutants to include a putative influence of the EHV-1 UL45 on cell fusion in our studies. RacH induces fusion of infected cells especially in cells of equine origin. The amino acid sequence of the RacH gB has been shown to carry several mutations compared to wild-type EHV-1 gB sequences (Neubauer et al., 1997b) , and the mutated gB has been connected with the distinct syncytial (syn) phenotype of RacH (Neubauer et al., 1997a) .
RESULTS

Identification of the EHV-1 UL45 protein
The rabbit antisera produced after immunization with either the UL45 peptide (UL45-P) or the 6-His-tagged UL45 protein (UL45-His) were tested for their ability to react specifically with EHV-1 by Western blot analysis. RacL22-infected cell lysates were harvested at 14 h p.i., subjected to SDS-PAGE, and incubated with the respective antibodies. Under denaturing conditions, both antisera reacted specifically with at least three protein species exhibiting M r s of 32,000, 40,000, and 43,000 (Fig. 2) . To confirm the specificity of the antiserum, anti-UL45-P was blocked by preincubation with the UL45-peptide against which it had been produced. After preincubation, the anti-UL45-P antiserum failed to react with any of the previously identified proteins in RacL22-infected cells (Fig. 2C) , whereas after blocking with an irrelevant peptide, the reactivity of the antiserum remained unaffected ( Fig. 2D) . However, the binding of the antiserum to higher M r proteins that frequently reacted in uninfected-and infected-cell lysates was not specifically blocked by the UL45 peptide (Fig. 2C) , and these reactions were considered unspecific. Due to its apparent higher sensitivity, the anti-UL45-His antiserum was chosen for most experiments in this study.
From the analysis of the UL45 protein moieties in infected cells, it was concluded that the EHV-1 UL45 protein is expressed as proteins of apparent M r s of 32,000, 40,000, and 43,000 in infected cells. To further analyze UL45 protein processing, RacL22-infected Edmin337 cells were harvested at 8 or 14 h p.i., lysed, mixed with sample buffer without addition of 2-mercaptoethanol, and subjected to SDS-PAGE without heating at 95°C. Western blot analysis revealed additional proteins of M r 60,000-90,000 that reacted specifically with the UL45-His antibody and which became prominent during infection (Fig. 3) . The fact that these high-M r proteins contained UL45 protein led to the conclusion that these bands arise by formation of UL45 homo-or heterodimers linked by disulfide bonds.
Synthesis and processing of the EHV-1 UL45 protein
To determine the kinetics of UL45 expression, Edmin337 cells were infected at an m.o.i. of 5 with EHV-1 strain RacL22. Infected cell lysates were prepared at different times postinfection, were adjusted to equal protein concentrations, and were subjected to Western blot analysis. Parallel blots were probed with the anti EHV-1 glycoprotein B (gB) antibody 3F6 (Allen and Yeargan, 1987) or with anti-UL45-His. The results of this experiment are shown in Fig. 4 . Although the early-late (␤Ϫ␥) gB was detected as early as 5 h p.i. (Fig. 4B) , the EHV-1 UL45 protein could not be detected until 8 h p.i. (Fig. 4A) . It was noted that the intensity of the M r 32,000 UL45 moiety increased Յ10 h p.i. Thereafter, the intensity of the lower-M r UL45 band decreased, whereas the intensities of the UL45 proteins of M r 40,000 and 43,000 increased with time p.i. (Fig. 4A) .
The expression kinetics of the EHV-1 UL45-protein was assessed further in experiments using PAA to block viral DNA synthesis. Edmin337 cells were infected at an m.o.i. of 5 with RacL22 and were incubated in the presence of various concentrations of PAA (0.1, 0.5, and 1.0 mg/ml medium). Infected cells were lysed at 14 h p.i. and were analyzed by SDS-PAGE and Western blotting. Relative to the concentration of PAA added, the amount of UL45 protein decreased and was absent in the presence of 0.5 mg of the drug. In contrast gB, which represents a ␤Ϫ␥ protein, remained detectable even in the presence of 1.0 mg of PAA (Fig. 5) . From the expression kinetics and the PAA experiments, it was concluded that EHV-1 UL45 is expressed as a true late (␥-2) protein.
The EHV-1 UL45 protein is N-glycosylated and represents a class II membrane glycoprotein
The following series of experiments addressed the putative N-or O-glycosylation of the UL45 protein because the amino acid sequence of the EHV-1 UL45 protein carries a putative membrane anchor and three N-glycosylation consensus sites that could theoretically be used if the protein was present in a type II orientation within membranes. In addition, glycosylation could explain the migration pattern of the UL45-specific proteins observed in infected cell lysates. Initially, the possibility of membrane association for the UL45 protein was addressed. RacL22-infected cells (m.o.i. of 5) were harvested at 14 h p.i. and separated into fractions (Bogner et al., 1992) . All fractions were adjusted to the same protein concentrations and subjected to Western blot analysis. gB-specific bands were detected with MAb 3F6 in nuclear as well as membrane fractions but not in the soluble cytoplasmic fraction, thus confirming the identity of the fractions (data not shown). With the anti-UL45-His antibody, there was a clear reactivity in the fraction containing cellular membranes, a weaker reactivity in the nuclear fraction and no reactivity at all in the soluble fraction (Fig. 6A ). These data support an association of the EHV-1 UL45 with cellular membranes.
Two approaches were taken to analyze the putative N-glycosylation of the UL45 protein. First, Rk13 cells were infected at an m.o.i. of 5 with RacL22 for 14 h in the presence or absence of tunicamycin (Fig. 6B) . Second, infected cell lysates were treated with PNGase F (Fig.  6C ). Western blots of the cell lysates treated as described above were incubated with the anti-UL45-His antibody or with anti-gB MAb 3F6 as a control. As expected, the electrophoretic mobility of gB-specific bands increased both after incubation with tunicamycin and after enzymatic deglycosylation (data not shown). The distinct pattern of UL45-specific bands disappeared after incubation of infected cells in the presence of tunicamycin and after enzymatic deglycosylation using PNGaseF, and a single protein species of M r 24,000 was detected using the anti-UL45 antibody (Figs. 6B and 6C). UL45 protein processing was analyzed further by enzymatic deglycosylation using EndoH, which removes high-mannose glycans. As shown in Fig. 6D , the M r 32,000 UL45 protein was absent after EndoH treatment, whereas the M r 40,000 and 43,000 UL45 moiety remained unaffected. Finally, enzymatic deglycosylation using a combination of neuraminidase and O-glycosidase was performed. No alteration of the electrophoretic mobilities of the various UL45 protein moieties was observed, thereby excluding addition of O-linked glycans to the UL45 polypeptide (data not shown). The M r 24,000 UL45 protein species (Figs. 6B-6D) corresponded quite well to the predicted M r of 23,798 and was therefore interpreted to be the nonglycosylated backbone of UL45.
The above observation that the EHV-1 UL45 protein is modified by addition of N-linked carbohydrates is only possible if the protein represents a type II transmembrane protein as reported for the HSV-2 UL45 homolog (Cockrell and Muggeridge, 1998) . Other samples were treated with EndoH as described under Materials and Methods. All lysates were subjected to 12% PAGE, and the blots shown were incubated with anti-UL45-HIS. Molecular weights are shown in thousands.
EHV-1 UL45 is not incorporated in extracellular virions
RacL22 and RacH virions were purified over a sucrose cushion, checked for purity by electron microscopy, and analyzed by Western blotting. Identical blots were probed either with anti-UL45-His or with the anti EHV-1 gB MAb 3F6. In extracellular virions, only the 75,000 M r , completely processed large subunit (Sullivan et al., 1989) of gB was detectable (Fig. 7B) . In contrast, no signal with the UL45-His antibody was obtained (Fig. 7A ), even at longer exposure times. The strength of the gB signal and lack of UL45-specific reactivity in purified virus preparations suggest that the EHV-1 UL45 protein is not incorporated into extracellular EHV-1 virions.
EHV-1 UL45 is nonessential for virus growth in cell culture
To investigate the role of EHV-1 UL45 in cell culture, UL45 deletion mutants from strains RacL22 and RacH were engineered. To this end, plasmid p45GFPϩ was inserted into the genomes of RacL22 and RacH, respectively, by homologous recombination (Figs. 1A and 1B) . The resulting recombinant viruses, L⌬45 and H⌬45, were purified to homogeneity on Rk13 cells by four rounds of plaque purification. Similarly, the repaired viruses R-L45 and R-H45 were isolated after cotransfection of L⌬45 or H⌬45 DNA with the 7348-bp BamHI-h fragment by selection for nonfluorescing plaques.
All recombinant viruses, as well as the parental virus strains, were characterized by Southern blot analysis. Viral DNA from UL45-negative, repaired, and parental viruses, i.e., RacL22, L⌬45, R-L45, RacH, H⌬45, and R-H45 was prepared, digested with either BamHI or EcoRI, and analyzed by Southern blotting. The correct insertion of the GFP gene (L⌬45 and H⌬45), or the re-insertion of the UL45 gene in the case of R-L45 and R-H45, was confirmed using probes specific for the GFP gene or the UL45 gene (data not shown).
The fact that we were able to isolate H⌬45 and L⌬45 on Rk13 cells clearly demonstrated that UL45 is not essential for virus replication in vitro. To further characterize the growth properties of H⌬45 and L⌬45, a series of experiments was conducted. First, expression of late genes and the absence of the UL45 protein were analyzed in Rk13 cells infected at an m.o.i. of 5 with RacL22, RacH, the UL45-negative viruses, or the repaired viruses. Infected cell lysates (14 h p.i.) were analyzed by Western blotting using the anti UL45-His antibody, anti-gB MAb 3F6, an anti-gD antibody, or anti gM-MAb B8. As shown in Fig. 8 , reactivity of gB, gD, and gM was detected readily in lysates of cells infected with parental or with UL45-negative viruses. These results indicated not only that an equivalent amount of infected cells had been used for the experiment but also that the production of late, structural proteins such as gB, gD, or gM appeared unaffected by the deletion of UL45. In contrast, UL45-specific reactivity was detected in lysates of cells infected with the parental viruses or the repaired viruses but not in lysates of cells infected with L⌬45 or H⌬45, thus demonstrating the absence of the UL45 gene in the engineered mutants (Fig. 8) .
Because the transcript of the gene adjacent to UL45, the EHV-1 gC-gene, is 3Ј-coterminal with the UL45 transcript (Matsumura et al., 1993) , we sought to confirm that expression of gC was not affected by the deletion of UL45 and insertion of the GFP cassette. To this end, Rk13 cells in six-well plates were infected with 30 PFU of parental, UL45-negative, or repaired viruses and were analyzed by IIF using anti EHV-1 gC MAb 2A2 or anti-gB MAb 3F6. It was demonstrated that gC-and gB-specific reactivity were indistinguishable, irrespective of whether L⌬45 and H⌬45 or any of the parental or repaired viruses had been used for infection (data not shown). It was concluded, therefore, that the replacement of 646 bp of EHV-1 sequences by the GFP-expression cassette of 1487 bp did not influence the correct expression of the adjacent gC gene.
To test whether deletion of the UL45 protein influences viral entry, virus penetration assays were performed. Because the UL45 protein had not been detected in extracellular virions, no direct influence of the UL45 protein on virus entry was expected. Accordingly, the penetration experiments demonstrated that H⌬45 and L⌬45 are able to enter Rk13 cells, and no significant difference in the kinetics of virus penetration with either parental or repaired viruses was observed (Fig. 9) .
In the following experiments, single-step growth kinetics of UL45-negative and parental or repaired viruses were performed. Rk13 or Edmin337 cells in 24-well plates were infected at an m.o.i. of 10 with the respective viruses. Supernatants and infected cell pellets were harvested separately at various times p.i. (0, 3, 6, 8, 10, 12 , and 24 h). Supernatants were cleared of cellular debris by low-speed centrifugation, and cells were subjected to two rounds of freeze-thawing before cell-associated infectivity was assayed. All virus titers were determined individually on Rk13 cells in 24-well plates. The results can be summarized as follows: With the single exception of a 36-fold reduction in virus titers at 6 h p.i., cellassociated infectivity of H⌬45 was reduced by less than 5-fold on Rk13 cells compared to titers of cells infected with RacH (Fig. 10A) , supporting the initial observation that the UL45-negative viruses can replicate efficiently in cell culture. In contrast, extracellular virus titers of H⌬45 were reduced by Յ140-fold (12 h p.i.) compared to those of RacH (Fig. 10A) . Similarly, intracellular virus titers of cells infected with L⌬45 reached those of RacL22 at 24 h (factor 0.56; Fig. 10B ), whereas extracellular virus titers were reduced by ϳ130-fold at 12 h p.i. (Fig. 10B) . The difference in extracellular virus titers between UL45-negative and parental or repaired viruses was even more prominent at the beginning of the experiment (6 h), when no extracellular infectivity was detected for the UL45-negative viruses. In contrast, in supernatants of cells infected with either wild-type or repaired viruses, virus titers of Յ2.7 ϫ 10 2 were observed. The data are illustrated in Fig. 10 for Rk13 cells only because the reduction of extracellular virus titers of UL45-negative viruses on Edmin337 cells was very similar to that observed on Rk13 cells.
Following the single-step growth kinetics, the growth properties of the UL45-negative viruses after infection of Rk13 cells at different m.o.i.s were determined. The intracellular and extracellular virus titers of RacH, RacL22, H⌬45, L⌬45, R-H45, and R-L45 were determined at time point 0 and at 12, 24, and 48 h p.i. The extracellular titers of RacH, RacL22, or repaired viruses exceeded intracellular virus titers between 12 and 24 h, whereas extracel- lular titers of H⌬45 and L⌬45 did not reach intracellular virus titers at any time postinfection (data not shown).
Plaque phenotypes of H⌬45 and L⌬45, however, were not significantly altered compared to plaques observed after infection with parental or with repaired viruses on Rk13 cells as well as on Edmin337 cells. Only when in parallel cells in six-well plates were infected with the respective viruses (50 PFU) and incubated without any overlay for 3 days was a marked reduction in the ability to infect the entire monolayer observed for the UL45 deletion mutants compared to parental and repaired viruses (data not shown).
Taken together, these results led to the conclusion that the deletion of UL45 causes a massive defect in virus egress although production of late genes and the ability to spread from cell to cell appears unaffected.
DISCUSSION
In this communication, an initial characterization of the EHV-1 UL45 protein is presented. The salient findings of this study are: (i) the EHV-1 UL45 protein is a heavily N-glycosylated integral type II membrane protein; (ii) although expressed at late times postinfection and processed in the Golgi network, it is not incorporated into extracellular virions; and (iii) despite efficient replication of UL45-negative viruses on noncomplementing cells, deletion of UL45 affected viral egress reducing extracellular virus titers by up to 250-fold compared to titers of wild-type EHV-1.
The HSV-1, HSV-2, and the EHV-1 UL45-proteins are definitely related, structurally as well as functionally. On the one hand, they share not only a large internal hydrophobic domain but also a characteristic type II membrane orientation that has been shown experimentally for the HSV-2 (Cockrell and Muggeridge, 1998) and for the EHV-1 homolog (this study). On the other hand, they exhibit only very low amino acid identity (less than 25% to either HSV-1 or -2-as determined using program gap of the gcg software package), and the HSV-1 and HSV-2 homologs do not carry consensus N-glycosylation sites, while the EHV-1 UL45 and most probably other homologous UL45-proteins form a new family of herpesviral type II membrane glycoproteins.
The PrV US9 protein is a relatively well-studied tailanchored type II membrane protein that is thought to be inserted into membranes posttranslationally (Brideau et al., 1998 (Brideau et al., , 1999 . The EHV-1 UL45 protein, however, is an integral membrane protein and is inserted cotranslationally into the endoplasmatic reticulum where glycosylation as well as formation of disulfide-linked di-and oligomers is observed. The UL45-containing protein species of higher M r , which were demonstrated in this study, most probably represent homodimers as similar UL45-specific oligomers are observed in cells expressing the EHV-1 UL45 protein only (data not shown). In addition, the M r s of the UL45 oligomers correspond quite well to calculated molecular weights of dimers of the primarily and fully processed glycoproteins. As there are nine cystein residues present in the amino acid sequence of the EHV-1 UL45, formation of homodimers by means of disulfide bonds is very likely. Final protein processing takes place in the Golgi apparatus, paralleled by the occurrence of EndoH-resistant forms of the UL45 protein.
The occurrence of more then one EndoH-resistant form indicates that the UL45 protein undergoes several glycoforms while passing through the Golgi apparatus. Taking into account that N-glycosylation of only three possible consensus sites leads to an apparent shift in the M r of ϳ20,000, glycosylation of the EHV-1 UL45 protein seems to be very complex. This complexity could also explain the appearance of additional UL45 specific bands when the treatment of the lysates of infected cells is varied, for example, as seen in Fig. 3 , where various UL45 reactive proteins were detected between 32 and 45 kDa.
Technical problems, such as insufficient sensitivity of our antibody, cannot be excluded as the reason for failure to detect UL45 protein in purified extracellular virions. However, this is unlikely for the following reasons: It was not possible to detect UL45 proteins in numerous virion preparations, all of which contained at least 60% enveloped particles and were strongly reactive with the control antibody 3F6. This observation was corroborated by the fact that the UL45-negative viruses did not show an virus entry phenotype, although the latter could of course also be seen in a structural protein that simply does not function in virus entry. Therefore, the possibility that the EHV-1 UL45 protein represents a fully processed protein that is expressed late in infection and present in the TGN but is still not incorporated into virions has to be considered. It could be speculated that the UL45 protein may lack a signal necessary for the incorporation into extracellular virions or that it might be directed to another subcellular compartment after having exerted its function in virus maturation and egress. Consequently, one of our future aims will be to study the subcellular localization of the EHV-1 UL45 protein, e.g., degradation in lysosomes, at very late times postinfection.
The functional characterization of the UL45-negative EHV-1 in vitro indicated that the UL45 protein facilitates virus egress. First, it was shown in virus growth kinetics that the production of extracellular infectivity by the UL45-negative viruses was particularly reduced. Second, it was demonstrated that H⌬45 and L⌬45 were able to form plaques and infect neighboring cells but were impaired in the fast spread of infectivity throughout an entire cell monolayer. Taking into account that the ability of intracellular as well as extracellular UL45-negative virions to infect cells from outside is well conserved, the reason for the observed reduction in extracellular infectivity must be based on a reduction in a late step in the virus replication cycle. A general reduction in the efficiency of envelopment and/or transport of virions through and out of the cell could explain the marked reduction of extracellular titers paralleled by a slight reduction of intracellular titers. It has to be stressed at this point that no accumulation of infectious viruses in infected cells was observed that would allow the conclusion of the involvement of UL45 in a post-Golgi transport step only. That a nonstructural protein expressed late in infection is involved in virus egress processes seems consequent. However, the inability to confirm a role for EHV-1 UL45 in syncytia or generally in plaque formation, as has been shown for the HSV-1 UL45 product (Haanes et al., 1994; Visalli and Brandt, 1991) , was a surprise. Of course it has to be remembered that only two different cell systems in vitro were considered: Edmin337 cells, a permanent cell line of equine origin; and Rk13 cells, a rabbit cell line. The phenotype observed could possibly differ in another cell system. Additionally, the gB of RacH carries several mutations that could influence a putative interaction of gB and UL45 in syncytia formation. Last but not least, EHV-1 is not HSV-1, and UL45 could simply play another role in the EHV-1 system. By analyzing the expression of gC we were able to exclude an influence of a reduced gC expression on the phenotype of our UL45-negative viruses. A sufficient expression of gC was again supported by the fact that H⌬45 and L⌬45 were able to enter cells, whereas the entry of gC-negative EHV-1 is severely impaired (Osterrieder, 1999) . Therefore, in contrast to the studies on HSV-1 UL45 (Visalli and Brandt, 1991) , the results reported here can only be accounted for by the deletion of UL45 and thus represent the first thorough analysis of a UL45-negative herpesvirus in vitro.
MATERIALS AND METHODS
Plasmids
To express a portion of the UL45 gene as a 6-Hisfusion protein, the predicted hydrophilic portion of the UL45 ORF (bases 315-657) (Telford et al., 1992) was amplified by PCR and inserted into vector pQE32 (Qiagen) (Fig. 1C) . Correct amplification of the PCR product was confirmed by sequence analysis (MWG Biotech). The EHV-1 BamHI-h fragment in vector pTZ18R (Stratagene) (Osterrieder, 1999) was used for construction of UL45 knock-out plasmid p45GFPϩ (Fig. 1B) . After removal of one NruI site by SpeI and XbaI digestion (the latter in the multiple cloning site of pTZ18R) and subsequent religation, the majority of the UL45-gene was removed by digestion with BsmI and NruI (leaving the carboxylterminal 117 bp of UL45). A GFP-expression cassette released from plasmid pEGFP-C1 (Clontech) using BsmI and NsiI was inserted in parallel transcriptional orientation after blunt end modification of the NsiI site. The resulting plasmid p45GFPϩ is thus carrying the former 5591-bp BamHI-SpeI fragment of EHV-1 but with 82% of the UL45 gene (542 bp) plus 106 bp of the preceding noncoding region removed and substituted by the GFP cassette (Fig. 1B) .
Cells and viruses
The wild-type EHV-1 strain RacL22 and its attenuated cell culture derivative RacH (Hübert et al., 1996) were propagated in equine dermal cell line Edmin337 or on rabbit kidney cell line Rk13 (Neubauer et al., 1997b) . All cell lines were maintained in minimal essential medium supplemented with 10% fetal calf serum.
Generation of recombinant viruses
The UL45-negative EHV-1 cells were generated by cotransfection of Rk13 cells with 5 g of plasmid p45GFPϩ (Fig. 1b) and 1-2 g of DNA of RacH or RacL22, respectively. Supernatants of transfected cells were plated on Rk13 cells and GFP-positive fluorescing virus plaques, detected using an inverted fluorescence microscope (Axiovert, Zeiss), were isolated. Recombinant viruses were purified by four rounds of plaque isolation. Repaired viruses were generated by cotransfection of the BamHI-h fragment with DNA of the UL45-negative viruses. Recombinants were isolated by selection for nonfluorescing virus plaques.
Purification of extracellular virions
Edmin337 cells were infected at a m.o.i. of 5. At 14 h p.i., supernatants of infected cells were harvested. Cell detritus was removed by low-speed centrifugation. The virus suspension was layered carefully on a 30% sucrose cushion and centrifuged for 3 h at 23,000 g in a Beckman SW 28 rotor. The resulting pellet was resuspended in medium, and the centrifugation was repeated. The virions were resuspended in PBS, and the purity of virion preparations was examined by electron microscopy.
Southern blot analysis
Viral DNA was prepared from Rk13 cells infected with the various viruses. DNA was digested with the indicated restriction endonucleases, and the resulting fragments were transferred onto positively charged nylon membranes after separation in an 0.8% agarose gel, as previously described Neubauer et al., 1997b) . UL45 sequences released from pC45 (a plasmid carrying the UL45 ORF only) and the GFP sequences from pEGFP-C1 were labeled with digoxigenin 11-dUTP (Roche Molecular Biochemicals) by random priming and used as UL45-and GFP-specific probes. DNA hybrids were detected using an anti-digoxigenin alkaline phosphatase conjugate (Roche Molecular Biochemicals) and visualized with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate according to the manufacturer's instructions.
Antibodies
The monoclonal anti EHV-1-gB antibody 3F6 (Allen and Yeargan, 1987) , anti-EHV-1 gC monoclonal 2A2 (Osterrieder, 1999) , anti-EHV-1-gD polyclonal anti-19mer rabbit antibody (Flowers and O'Callaghan, 1992) , and anti EHV-1-gM monoclonal antibody B8 (Day, 1999) were used in this study. To generate UL45-specific antibodies, two different approaches were taken. First, a peptide corresponding to amino acids 32-56 of the deduced amino acid sequence of UL45 (Telford et al., 1992) was synthesized (MWG Biotech) (Fig. 1C) . The peptide was coupled to keyhole limpet hemocyanin (Sambrook et al., 1989) and 200 g of the coupled peptide was used for immunization of two rabbits. Second, a 6-His-tagged fusion protein (Fig. 1C) was expressed in Escherichia coli strain M15 and was purified using the Qiaexpress type IV expression and purification system following the manufacturer's instructions (Qiagen). The quantity and quality of the purified protein were confirmed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and subsequent Coomassie blue staining or Western blot analysis using the RGS-His Antibody (Qiagen). Two rabbits were immunized five times at 6-week intervals with 50-100 g of the purified protein.
Western blotting and indirect immunofluorescence
Edmin337 or Rk13 cells were infected at an m.o.i. of 5 with the respective viruses and cells were lysed at the indicated time points p.i. Lysates were adjusted to 1 mg/ml protein (BCA protein assay; Pierce), and sample buffer containing 5% 2-mercaptoethanol was added (Sambrook et al., 1989) . Samples were heated at 95°C for 5 min, and proteins were separated on SDS 12 or 15% polyacrylamide gels. Separated proteins were blotted onto nitrocellulose filters (Towbin et al., 1979) . Free binding sites on nitrocellulose membranes were blocked with 10% nonfat dry milk in PBS containing 0.05% Tween 20 (Sigma). Antibodies were added at the indicated concentrations for 1 h at RT. Antibody binding was visualized using anti-mouse or anti-rabbit immunoglobulin G (IgG) peroxidase conjugate (Sigma) followed by ECL detection (Pharmacia-Amersham).
For indirect immunofluorescence analysis (IIF), Rk13 cells infected for 14 h with the indicated viruses were fixed with 80% acetone. Unspecific binding was blocked with PBS containing 10% FCS for 45 min. After two washing steps with PBS, cells were incubated with the primary antibody for 30 min, washed again, and incubated for 30 min with the anti-rabbit or anti-mouse IgG Alexa 546 or Alexa 488 conjugates (Molecular Probes). After two final washing steps, probes were analyzed by fluorescence microscopy (Axiovert/Zeiss).
Analysis of protein synthesis and deglycosylation experiments
Inhibition of DNA synthesis, using phosphonoacetic acid (PAA), was achieved by addition of the drug (0.1, 0.5, or 1 mg/ml of medium) to Rk13 cells infected at an m.o.i. of 5 with RacL22. Infected cells were incubated for 14 h before cell lysates were prepared and subjected to SDS-PAGE.
To inhibit cotranslational N-glycosylation, Rk13 cells were infected at an m.o.i. of 5 with RacL22 and incubated for 14 h in the presence of tunicamycin (1.0, 5.0, or 10.0 g/ml medium) (Roche Molecular Biochemicals). N-linked carbohydrates were removed using N-glycosidase F (peptide-N-glycosidase F, Roche Molecular Biochemicals). At 14 h p.i., cells were resuspended in Nglycosidase F buffer (Osterrieder et al., 1997) and incubated for 16 h in the presence or absence of 0.1 or 0.4 U of N-glycosidase F. Endoglycosidase H (endo-␤-Nacetylglucosaminidase H, Roche Molecular Biochemicals,) was applied for 16 h at 37°C at 20 mU/100 l of infected cell lysate in a buffer containing Na 3 PO 4 (50 mM), SDS (0.2%), 2-mercaptoethanol (1%), and phenylmethylsulfonyl fluoride (PMSF, 0.5 mM). O-glycosylation was analyzed by adding 2 U of neuraminidase (Roche Molecular Biochemicals) to cells that had been infected for 14 h (RacL22), pelleted and freeze-thawed, broken by ultrasonic treatment, and resuspended in a sodium acetate (0.3 M; pH 5.2) and calcium chloride (0.1 M) solution. After 2 h incubation with neuraminidase at 37°C, proteins were pelleted and subsequently resuspended in Tris-phosphate buffer (20 mM, pH 7.4) and digested with 2 U of O-glycosidase (16 h, 37°C) (Roche Molecular Biochemicals).
Fractionation of cells
Fractionation of cells was as described by Bogner et al. (1992) . Briefly, Rk13 cells were infected with RacL22 at an m.o.i. of 5 for 14 h, washed with PBS, pelleted, and resuspended in fractionation buffer (5 mM Na phosphate, pH 7.5, 2 mM MgCl 2 , 0.5 mM CaCl 2 , 1 mM PMSF), and cells were broken by ultrasonic treatment. After addition of sucrose (ad 0.3 M), nuclei and cell detritus were pelleted at 800 g (10 min, pellet 1), followed by centrifugation at 10,000 g (10 min). The collected supernatant was separated by centrifugation at 100,000 g (1 h, 4°C) into a fraction containing the plasma membranes as well as vesicles from the endoplasmatic reticulum and Golgi network (pellet 2), and into a fraction (supernatant) containing the soluble components of the cytoplasm. Pellet 1 was resuspended in fractionation buffer, and nuclei were separated from remaining intact cells and cell detritus by centrifugation over a sucrose cushion (1.62 M). Finally, nuclei were lysed in fractionation buffer by addition of 0.5% Triton X-100.
Penetration assays
Penetration assays were performed as previously described Neubauer et al., 1997b) . Briefly, Rk13 cells grown on six-well plates were preincubated at 4°C for 30 min, infected with 100 PFU of the respective viruses, and incubated at 4°C for 90 min to allow virus absorption. The temperature was adjusted to 37°C, and at different times after temperature shift, extracellular virus was inactivated using a citrate buffer (pH 3.0) for 2 min. The percentage of plaques present after citrate treatment relative to the number of plaques present after control treatment (PBS) was determined.
Virus growth kinetics and plaque size measurements
Rk13 or Edmin337 cells seeded in 24-or 6-well plates were infected with the indicated viruses. After a 2-h absorption period at 4°C, viruses were allowed to penetrate for 90 min before remaining extracellular virus was inactivated using a citrate buffer (pH 3.0). At the indicated times, parallel samples of supernatants and infected cells were harvested. Titers of intracellular and extracellular virus were compared at each time point by plaque titration on Rk13 cells in 24-well plates. Plaque sizes on Rk13 or Edmin337 cells were determined as follows. Cells seeded on six-well plates were infected with 50 PFU per well of the respective viruses. Three days postinfection, the sizes of the plaques were determined by measuring the maximal diameter of 300 randomly selected plaques in the presence or absence of 0.25% methylcellulose.
